Codexis, Inc. - Common Stock (CDXS)
2.1100
-0.1800 (-7.86%)
NASDAQ · Last Trade: Apr 5th, 9:30 AM EDT
Detailed Quote
Previous Close | 2.290 |
---|---|
Open | 2.210 |
Bid | 2.020 |
Ask | 2.190 |
Day's Range | 2.000 - 2.250 |
52 Week Range | 2.000 - 6.080 |
Volume | 1,247,958 |
Market Cap | 136.39M |
PE Ratio (TTM) | -2.398 |
EPS (TTM) | -0.9 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,177,141 |
Chart
About Codexis, Inc. - Common Stock (CDXS)
Codexis Inc is a biotechnology company that focuses on the development and application of protein engineering technologies to create innovative solutions for various industries, including pharmaceuticals, biotechnology, and agriculture. The company leverages its proprietary CodeEvolver platform to design and optimize enzymes for improved performance and efficiency, facilitating the production of active pharmaceutical ingredients and other bio-based products. With a strong emphasis on sustainability and reducing environmental impact, Codexis aims to transform traditional manufacturing processes through its engineered proteins, thereby advancing the future of bioeconomy and contributing to healthier living. Read More
News & Press Releases

Via Benzinga · February 29, 2024

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via Benzinga · February 27, 2024

Via Benzinga · November 22, 2024

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (Nasdaq: CDXS), a leading enzyme engineering company, and was the former CTO of Allogene Therapeutics (Nasdaq: ALLO), a pioneering clinical-stage company advancing CAR T-cell therapies.
By Artiva Biotherapeutics, Inc. · Via GlobeNewswire · October 22, 2024

CDXS stock results show that Codexis missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024

CDXS stock results show that Codexis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 2, 2024

Via Benzinga · February 27, 2024

Via Benzinga · February 27, 2024

Via Benzinga · February 1, 2024

Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI).
Via Benzinga · December 27, 2023
“Dyadic International Inc. (NASDAQ: DYAI) Advances Biopharmaceutical Innovations and Vaccine Manufacturing Globally”
Dyadic International Inc. (NASDAQ: DYAI), a leading biotechnology firm, focuses on developing innovative microbial platforms to address the increasing global demand for protein bioproduction. Furthermore, the company aims to fulfil unmet clinical and industrial needs by providing cost-effective, accessible, and efficient biopharmaceutical products for both human and animal applications.
Via AB Newswire · December 21, 2023

Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.
Via Benzinga · December 14, 2023

Via Benzinga · December 14, 2023

Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors. Nxu, shares rose 42.1% to $0.0278 in pre-market trading. Here are some other stocks moving in pre-market trading.
Via Benzinga · December 14, 2023

Via Benzinga · December 14, 2023

Via Benzinga · December 13, 2023

Synthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks.
Via InvestorPlace · November 29, 2023

While trying to find the next Nvidia is a wildly risky proposition, these AI stocks to buy could be your ticket to extraordinary gains.
Via InvestorPlace · September 16, 2023

Via Benzinga · September 12, 2023

Via Benzinga · August 22, 2023

Via Benzinga · August 21, 2023

Via Benzinga · August 14, 2023

Codexis Inc (NASDAQ: CDXS) intends to prioritize advancing and commercializing its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis platform and its
Via Benzinga · July 21, 2023